Literature DB >> 32515821

Screening for Unhealthy Drug Use: US Preventive Services Task Force Recommendation Statement.

Alex H Krist1,2, Karina W Davidson3, Carol M Mangione4, Michael J Barry5, Michael Cabana6, Aaron B Caughey7, Susan J Curry8, Katrina Donahue9, Chyke A Doubeni10, John W Epling11, Martha Kubik12, Gbenga Ogedegbe13, Lori Pbert14, Michael Silverstein15, Melissa A Simon16, Chien-Wen Tseng17,18, John B Wong19.   

Abstract

IMPORTANCE: An estimated 12% of adults 18 years or older and 8% of adolescents aged 12 to 17 years report unhealthy use of prescription or illegal drugs in the US.
OBJECTIVE: To update its 2008 recommendation, the USPSTF commissioned reviews of the evidence on screening by asking questions about drug use and interventions for unhealthy drug use in adults and adolescents. POPULATION: This recommendation statement applies to adults 18 years or older, including pregnant and postpartum persons, and adolescents aged 12 to 17 years in primary care settings. This statement does not apply to adolescents or adults who have a currently diagnosed drug use disorder or are currently undergoing or have been referred for drug use treatment. This statement applies to settings and populations for which services for accurate diagnosis, effective treatment, and appropriate care can be offered or referred. EVIDENCE ASSESSMENT: In adults, the USPSTF concludes with moderate certainty that screening by asking questions about unhealthy drug use has moderate net benefit when services for accurate diagnosis of unhealthy drug use or drug use disorders, effective treatment, and appropriate care can be offered or referred. In adolescents, because of the lack of evidence, the USPSTF concludes that the benefits and harms of screening for unhealthy drug use are uncertain and that the balance of benefits and harms cannot be determined. RECOMMENDATION: The USPSTF recommends screening by asking questions about unhealthy drug use in adults 18 years or older. Screening should be implemented when services for accurate diagnosis, effective treatment, and appropriate care can be offered or referred. (Screening refers to asking questions about unhealthy drug use, not testing biological specimens.) (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for unhealthy drug use in adolescents. (I statement).

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32515821     DOI: 10.1001/jama.2020.8020

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  32 in total

1.  Medically treated opioid overdoses among New Jersey Medicaid beneficiaries: Rapid growth and complex comorbidity amid growing fentanyl penetration.

Authors:  Stephen Crystal; Molly Nowels; Mark Olfson; Hillary Samples; Arthur Robinson Williams; Peter Treitler
Journal:  J Subst Abuse Treat       Date:  2021-06-24

2.  Clinician Perceptions About a Decision Support System to Identify and Manage Opioid Use Disorder.

Authors:  Leif I Solberg; Stephanie A Hooker; Rebecca C Rossom; Anna Bergdall; Benjamin F Crabtree
Journal:  J Am Board Fam Med       Date:  2021 Nov-Dec       Impact factor: 2.657

3.  Substance use disorders among primary care patients screening positive for unhealthy alcohol use.

Authors:  Verena E Metz; Vanessa A Palzes; Andrea Hessel Kline-Simon; Felicia W Chi; Cynthia I Campbell; Constance M Weisner; Stacy A Sterling
Journal:  Fam Pract       Date:  2022-03-24       Impact factor: 2.267

4.  Validation of the tobacco, alcohol, prescription medication, and other substance use (TAPS) tool with the WHO alcohol, smoking, and substance Involvement screening test (ASSIST).

Authors:  Gentry Carter; Ziji Yu; M Aryana Bryan; Jennifer L Brown; T Winhusen; Gerald Cochran
Journal:  Addict Behav       Date:  2021-11-10       Impact factor: 3.913

5.  Prescription drug and alcohol simultaneous co-ingestion in U.S. young adults: Prevalence and correlates.

Authors:  Ty S Schepis; Sean Esteban McCabe; Jason A Ford
Journal:  Exp Clin Psychopharmacol       Date:  2021-08-19       Impact factor: 3.157

6.  Cannabis use, other drug use, and risk of subsequent acute care in primary care patients.

Authors:  Theresa E Matson; Gwen T Lapham; Jennifer F Bobb; Eric Johnson; Julie E Richards; Amy K Lee; Katharine A Bradley; Joseph E Glass
Journal:  Drug Alcohol Depend       Date:  2020-08-08       Impact factor: 4.492

7.  Comparison of Methods for Alcohol and Drug Screening in Primary Care Clinics.

Authors:  Jennifer McNeely; Angéline Adam; John Rotrosen; Sarah E Wakeman; Timothy E Wilens; Joseph Kannry; Richard N Rosenthal; Aimee Wahle; Seth Pitts; Sarah Farkas; Carmen Rosa; Lauren Peccoralo; Eva Waite; Aida Vega; Jennifer Kent; Catherine K Craven; Tamar A Kaminski; Elizabeth Firmin; Benjamin Isenberg; Melanie Harris; Andre Kushniruk; Leah Hamilton
Journal:  JAMA Netw Open       Date:  2021-05-03

8.  Sexual orientation and gender identity disparities in co-occurring depressive symptoms and probable substance use disorders in a national cohort of young adults.

Authors:  Jennifer K Felner; Sean J Haley; Hee-Jin Jun; Jennifer P Wisdom; Laura Katuska; Heather L Corliss
Journal:  Addict Behav       Date:  2021-01-07       Impact factor: 3.913

9.  Evidence-Based Treatment of Young Adults With Substance Use Disorders.

Authors:  Scott E Hadland; Amy M Yule; Sharon J Levy; Eliza Hallett; Michael Silverstein; Sarah M Bagley
Journal:  Pediatrics       Date:  2021-01       Impact factor: 7.124

10.  The latent class structure of substance use in US adults 50 years and older.

Authors:  Ty S Schepis; Sean Esteban McCabe
Journal:  Int J Geriatr Psychiatry       Date:  2021-08-09       Impact factor: 3.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.